Alimera Sees Bright Spots in 2018

Dan Myers, CEO of Alimera Sciences, says company growth is moving the firm into cash-positive territory in 2018. What challenges did he have to conquer along the way to bring Iluvien to market as a treatment for diabetic macular edema?

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.